Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-18T10:30:19.297Z Has data issue: false hasContentIssue false

14 - Integrating theory, practice and economics in psychopharmacology

Published online by Cambridge University Press:  22 August 2009

By
Keh-Ming Lin ,
Chun-Yu Chen ,
Chia-Hui Chen ,
Jur-Shan Cheng  and
Sheng-Chang Wang
Edited by
Chee H. Ng ,
Keh-Ming Lin ,
Bruce S. Singh  and
Edmond Y. K. Chiu
Keh-Ming Lin
Affiliation:
Division of Mental Health and Substance Abuse Research, National Health Research Institutes, Taiwan
Chun-Yu Chen
Affiliation:
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan
Chia-Hui Chen
Affiliation:
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan
Jur-Shan Cheng
Affiliation:
Center for Health Policy Research and Development, National Health Research Institutes, Taiwan
Sheng-Chang Wang
Affiliation:
Division of Mental Health and Substance Abuse Research National Health Research Institutes, Taiwan
Chee H. Ng
Affiliation:
University of Melbourne
Keh-Ming Lin
Affiliation:
National Health Research Institutes, Taiwan
Bruce S. Singh
Affiliation:
University of Melbourne
Edmond Y. K. Chiu
Affiliation:
University of Melbourne
Get access

Summary

Critiques and reservations regarding the role and contribution of psychotropic agents in the care of psychiatric patients notwithstanding (Moncrieff, 2001; Healy, 2002), there is little doubt that the advent of modern psychopharmacology in the 1950s has vastly and profoundly altered the landscape of psychiatry. Phenothiazines and related compounds in the past half century have enabled millions of severely mentally ill patients to escape the fate of lifelong confinement. “Antidepressants” and mood stabilizers, equally serendipitously discovered around the same time, often effectively, and at times truly miraculously, lifted millions from various forms of misery. Together they also helped to change (albeit not fast enough and still a long way to go) the public's perception of the mentally ill as well as the professions charged with their care, helping to destigmatize behavioral and emotional problems. Irrespective of the extent of their therapeutic effects, the fact that simple chemical compounds could so profoundly alter behavior was itself inspiring for a new generation of scientists, who helped to usher in a new era of intensive research for the biological substrates of psychiatric phenomena, resulting in the blossoming of biological psychiatry and neuroscience in the last few decades (Carlsson, 1988; Bloom & Kupfer, 1995).

To be sure, examined at closer range, the effect of this “paradigm shift” on the profession and for society is far more complex and nuanced. Advances on the biological front not infrequently have been regarded as threats for our field's expertise in the psychosocial domains.

Type
Chapter
Information
Ethno-psychopharmacology
Advances in Current Practice
 , pp. 158 - 168
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aaserud, M., Dahlgren, A. T., Kösters, J. P.et al. (2006). Pharmaceutical policies: effects of ref- erence pricing, other pricing, and purchasing policies.Cochrane Database Syst. Rev., 19(2), CD005979.Google Scholar
Alarcón, R. D., Alegria, M., Bell, C. C.et al. (2002). Chapter 6. Beyond the funhouse mirrors. In D. J. Kupfer, M. B. First and D. A. Regier, eds., A Research Agenda for DSM-V. American Psychiatric Association, 219–81.Google Scholar
Banks, W. A. (2006). The blood–brain barrier in psychoneuroimmunology.Neurol. Clin., 24(3), 413–19.Google Scholar
Block, M. L. & Hong, J. S. (2005). Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism.Prog. Neurobiol., 76(2), 77–98.Google Scholar
Bloom, F. E. & Kupfer, D. J., eds. (1995). Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press.
Cabana, M. D., Rand, C. S., Powe, N. R.et al. (1999). Why don't physicians follow clinical practice guidelines? A framework for improvement.J.A.M.A., 282(15), 1458–65.Google Scholar
Carlsson, A. (1988). The current status of the dopamine hypothesis of schizophrenia.Neuropsychopharmacology, 1(3), 179–86.Google Scholar
Charney, D. S., Barlow, D. H., Botteron, K.et al. (2002). Chapter 2. Neuroscience research agenda to guide development of a pathophysiologically based classification system. In D. J. Kupfer, M. B. First and D. A. Regier, eds., A Research Agenda for DSM-V. American Psychiatric Association, pp. 31–84.Google Scholar
Chen, M.-L. & Chen, C.-H. (2005a). Comparative proteome analysis revealed up-regulation of transthyretin in rat brain under chronic clozapine treatment.J. Psychiatric Res., 41(1/2), 63–8.Google Scholar
Chen, M.-L. & Chen, C.-H. (2005b). Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment.Neuropsychopharmacology, 30(2), 268–77.Google Scholar
Cook, D. & Giacomini, M. (1999). The trials and tribulations of clinical practice guidelines.J.A.M.A., 281(20), 1950–1.Google Scholar
Dantzer, R. (2006). Cytokine, sickness behavior, and depression.Neurol. Clin., 24(3), 441–60.Google Scholar
Dawes, M., Davies, P., Gray, A.et al. (2005). Evidence-Based Practice: A Primer for Health Care Professionals. Edinburgh: ElsevierChurchill Livingstone.
Leon, J. (2006). AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.Expert Rev. Mol. Diagn., 6, 277–86.Google Scholar
Debouck, C. & Goodfellow, P. N. (1999). DNA microarrays in drug discovery and development.Nat. Genet., 21, 48–50.Google Scholar
Domino, E. F. (1999). History of modern psychopharmacology: a personal view with an emphasis on antidepressants.Psychosom. Med., 61(5), 591–8.Google Scholar
Duman, R. S. & Monteggia, L. M. (2006). A neurotrophic model for stress-related mood disorders.Biol. Psychiatry, 59(12), 1116–27.Google Scholar
Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S. & Schulman, K. A. (2005). Implications of pharmacogenomics for drug development and clinical practice.Arch. Intern. Med., 165(20), 2331–6.Google Scholar
Graham, J., Christian, L. & Kiecolt-Glaser, J. (2006). Stress, age, and immune function: toward a lifespan approach.J. Behav. Med., 29, 389–400.Google Scholar
Green, M. F. & Braff, D. L. (2001). Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications.Biol. Psychiatry 49(4), 374–84.Google Scholar
Hallworth, M. J. (2004). The drugs dont work: pharmacogenomics – clinical biochemistry's future?Ann. Clin. Biochem., 41, 260–2.Google Scholar
Healy, D. (2002). The Creation of Psychopharmacology.Cambridge, MA: Harvard University Press.
Hyman, S. E. & Nestler, E. J. (1996). Initiation and adaptation: a paradigm for understanding psychotropic drug action.Am. J. Psychiatry, 153(2), 151–62.Google Scholar
Ishikawa, T., Onishi, Y., Hirano, H.et al. (2004). Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1).Biol. Pharm. Bull., 27, 939–48.Google Scholar
Jadad, A. R. (1998). Randomised Controlled Trials: A User's Guide. London: BMJ Publishing Group.
Kempermann, G. & Kronenberg, G. (2003). Depressed new neurons? Adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression.Biol. Psychiatry, 54(5), 499–503.Google Scholar
Kendler, K. S. (2005). Toward a philosophical structure for psychiatry.Am. J. Psychiatry, 162(3), 433–40.Google Scholar
Kim, S. U. & Vellis, J. (2005). Microglia in health and disease.J. Neurosci. Res., 81(3), 302–13.Google Scholar
Kirchheiner, J., Bertilsson, L., Bruus, H.et al. (2003). Individualized medicine – implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.Pharmacopsychiatry, 36, 235–43.Google Scholar
Kirchheiner, J., Nickchen, K., Bauer, M.et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.Mol. Psychiatry, 9, 442–73.Google Scholar
Kremer, M. (2002). Pharmaceuticals and the developing world.J. Econ. Perspect., 16(4), 67–90.Google Scholar
Landon, M. R. (2005). Ethics and policy perspectives on personalized medicine in the post-genomic era.J. Biolaw Bus., 8(3), 28–36.Google Scholar
Lebowitz, B. D. & Rudorfer, M. V. (1998). Treatment research at the millennium: from efficacy to effectiveness.J. Clin. Psychopharmacol., 18(1), 1.Google Scholar
Lee, H.-J., Cha, J.-H., Ham, B.-J.et al. (2004). Association between a G-protein bold beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders.Pharmacogenomics J., 4, 29–33.Google Scholar
Leonard, B. E. & Myint, A. (2006). Changes in the immune system in depression and dementia: causal or coincidental effects?Dialogues Clin. Neurosc., 8(2), 163–74.Google Scholar
Lieberman, J. A., Stroup, T. S., McEvoy, J. P.et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N. Engl. J. Med., 353(12), 1209–23.Google Scholar
Lin, K.-M. & Lin, M. (2002). Chapter 5. Challenging the Myth of a Culture-free Nosological System. In K. Kurasaki, S. Okazaki and S. Sue, eds., Asian American Mental Health: Assessment Theories and Methods. New York: Plenum, pp. 67–73.
Luhrmann, T. M. (2000). Of Two Minds: The Growing Disorder in American Psychiatry. New York: Knopf.
Malhotra, A. K., Murphy, G. M., Jr. & Kennedy, J. L. (2004). Pharmacogenetics of psychotropic drug response.Am. J. Psychiatry, 161(5), 780–96.Google Scholar
Manji, H. K., Quiroz, J. A., Sporn, J.et al. (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.Biol. Psychiatry, 53(8), 707–42.Google Scholar
Martinelli, C. & Reichhart, J.-M. (2005). Evolution and integration of innate immune systems from fruit flies to man: lessons and questions.J. Endotoxin Res., 11, 243–8.Google Scholar
Matowe, L. & Katerere, D. R. (2002). Globalization and pharmacy: a view from the developing world.Ann. Pharmacother., 36(5), 936–8.Google Scholar
McIntyre, J. S. (2002). Usefulness and limitations of treatment guidelines in psychiatry.World Psychiatry, 1(3), 186–9.Google Scholar
Moncrieff, J. (2001). Are antidepressants overrated? A review of methodological problems in antidepressant trials.J. Nerv. Ment. Dis., 189(5), 288–95.Google Scholar
Müller, N. & Schwarz, M. J. (2006). Neuroimmune endocrine crosstalk in schizophrenia and mood disorders.Expert Rev. Neurother., 6, 1017–38.Google Scholar
NIMH (1998). Bridging Science and Service. A report by the National Advisory Mental Health Council's Clinical Treatment and Services Research Workgroup. Washington, D. C.
NIMH (2001). An Investment in America's Future: Racial/Ethnic Diversity in Mental Health Research Careers. Report of the National Advisory Mental Health Council Workgroup on Racial/Ethnic Diversity in Research Training and Health Disparities Research. Washington, D.C.
NIMH (2005). Treatment Research in Mental Illness: Improving the Nation's Public Mental Health Care through NIMH Funded Interventions Research. Report of the National Advisory Mental Health Council's Workgroup on Clinical Trials. Washington, D. C.
Paul, N. W. & Fangerau, H. (2006). Why should we bother? Ethical and social issues in individualized medicine.Curr. Drug Targets, 7, 1721–7.Google Scholar
Perlis, R. H., Ganz, D. A., Avorn, J.et al. (2005). Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model.J. Clin. Psychopharmacol., 25(5), 427–34.Google Scholar
Rapaport, M. H., Delrahim, K. K., Bresee, C. J.et al. (2005). Celecoxib augmentation of continuously ill patients with schizophrenia.Biol. Psychiatry, 57(12), 1594–6.Google Scholar
Rogers, E. M. (1995). Diffusion of Innovations. New York: Free Press.
Roses, A. D. (2001). Pharmacogenetics.Hum. Mol. Genet., 10, 2261–7.Google Scholar
Rush, A. J., Fava, M., Wisniewski, S. R.et al. (2004). Sequenced treatment alternatives to relieve depression (STAR∗D): rationale and design.Controlled Clinical Trials, 25(1), 119–42.Google Scholar
Russo-Neustadt, A. A. & Chen, M. J. (2005). Brain-derived neurotrophic factor and antidepressant activity.Curr. Pharm. Des., 11, 1495–510.Google Scholar
Schechter, L. E., Ring, R. H., Beyer, C. E.et al. (2005). Innovative approaches for the development of antidepressant drugs: current and future strategies.NeuroRx, 2(4), 590–611.Google Scholar
Serretti, A. & Smeraldi, E. (2004). Neural network analysis in pharmacogenetics of mood disorders.BMC Med. Genet., 5(1), 27.Google Scholar
Serretti, A., Cusin, C., Rossini, D.et al. (2004). Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.Am. J. Med. Genet. B Neuropsychiatr. Genet., 129B(1), 36–40.Google Scholar
Serretti, A., Benedetti, F., Zanardi, R. & Smeraldi, E. (2005). The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments.Prog. Neuro psychopharmacol. Biol. Psychiatry, 29(6), 1074–84.Google Scholar
Stahl, S. M. (2006). Finding what you are not looking for: strategies for developing novel treatments in psychiatry.NeuroRx, 3(1), 3–9.Google Scholar
Tucker, G. (2004). Pharmacogenetics – expectations and reality.B.M.J. 329(7456), 4–6.Google Scholar
Weinshilboum, R. & Wang, L. (2004). Pharmacogenomics: bench to bedside.Nat Rev. Drug Discov., 3(9), 739–48.Google Scholar
Wells, K. B. (1999). Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research.Am. J. Psychiatry, 156(1), 5–10.Google Scholar
Yoshida, K., Takahashi, H., Higuchi, H.et al. (2004). Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.Am. J. Psychiatry, 161(9), 1575–80.Google Scholar
Ziv, Y., Ron, N., Butovsky, O.et al. (2006). Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood.Nat. Neurosci., 9(2), 268–75.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×